Business Daily from THE HINDU group of publications
Sunday, Oct 01, 2006
ePaper


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Mergers & Acquisitions
Lupin not to buy Artifex Finance

Our Bureau

Mumbai , Sept. 30

Lupin Ltd will not pursue the memorandum of understanding that it signed in May this year to acquire 51 per cent equity in Belgium's Artifex Finance CVA, along with its subsidiaries including Dafra Pharma Ltd, a company focused on anti-malarials. "Based on subsequent discussions, both the parties have now mutually agreed not to pursue the said MoU and to independently pursue their respective business plans and continue discussions for possible areas of co-operation in the future," the company told the Bombay Stock Exchange.

The Lupin's Managing Director, Dr Kamal K Sharma, however, maintains that Lupin continues to be interested in anti-malarials.

A company source familiar with the development told Business Line that the MoU was to do the due diligence. It was found that the two companies could collaborate without getting into a formalised venture, he said.

It is likely that the two companies could partner to develop products together and sell them into international markets, the source added.

More Stories on : Mergers & Acquisitions | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Business Line — Paper size & print area reduction


ECB cap may be raised
Award for BEML chief
Lupin not to buy Artifex Finance
Gujarat Heavy scouting for more acquisitions
ONGC record date for bonus share
Force Motors plans entry into bus segment with MAN next year
Reliance in a fix over `rescue ship' directive
ECIL has new CMD


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line